Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention and using direct oral anticoagulants

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mr Oskar Love Emilsson

Lund (Sweden)

4 More presentations in this session

Presentation thumbnail

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents

Doctor M. Susanti (Jawa Timur, ID)

Abstract Slides Video

Presentation thumbnail

Impact of Beta-Blocker Prescription at Discharge on Long-term Clinical Outcomes in ST elevation Myocardial Infarction Patients with Reduced LVEF treated with Drug-eluting Stents

Professor S. Park (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Early initiation of PCSK9 inhibitors in acute STEMI: Interim results of safety and efficacy from the EARLY-STEMI trial

Doctor M. Ali (Doha, QA)

Abstract Slides Video

Presentation thumbnail

Efficacy and safety of ticagrelor versus clopidogrel in acute myocardial infarction-associated cardiogenic shock: a propensity score-matched analysis

Doctor M. Presume (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Pharmacotherapy in acute coronary syndromes (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Session

Oral antiplatelet therapy after acute coronary syndromes: how to choose the best regimen and the optimum duration

Congress Session

Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention

Congress Session

Pharmacotherapy in acute coronary syndromes

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources